Market Closed -
Nasdaq
04:00:00 2024-06-11 pm EDT
|
5-day change
|
1st Jan Change
|
2.74
USD
|
+1.86%
|
|
+3.40%
|
+9.60%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
116.9
|
160.7
|
200.1
|
38.07
|
20.65
|
36.62
|
-
|
-
|
Enterprise Value (EV)
1 |
97.52
|
156.8
|
200.1
|
38.07
|
20.65
|
36.62
|
36.62
|
36.62
|
P/E ratio
|
-5.11
x
|
-5.2
x
|
-3.01
x
|
-0.49
x
|
-0.67
x
|
-0.99
x
|
-1.61
x
|
-1.93
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
132
x
|
25.9
x
|
6.8
x
|
13.7
x
|
24.3
x
|
7.58
x
|
3.24
x
|
EV / Revenue
|
-
|
132
x
|
25.9
x
|
6.8
x
|
13.7
x
|
24.3
x
|
7.58
x
|
3.24
x
|
EV / EBITDA
|
-5.34
x
|
-5.08
x
|
-5
x
|
-0.75
x
|
-1
x
|
-10.5
x
|
-1.84
x
|
-2.14
x
|
EV / FCF
|
-5,667,563
x
|
-5,907,633
x
|
-5,240,970
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.74
x
|
4.93
x
|
3.07
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,599
|
3,363
|
4,612
|
5,932
|
8,261
|
13,365
|
-
|
-
|
Reference price
2 |
45.00
|
47.80
|
43.40
|
6.418
|
2.500
|
2.740
|
2.740
|
2.740
|
Announcement Date
|
3/25/20
|
3/16/21
|
3/10/22
|
3/31/23
|
4/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
1.216
|
7.727
|
5.6
|
1.503
|
1.506
|
4.829
|
11.3
|
EBITDA
1 |
-21.9
|
-31.64
|
-40.03
|
-50.71
|
-20.56
|
-3.5
|
-19.9
|
-17.1
|
EBIT
1 |
-22.24
|
-29.71
|
-74.21
|
-72.29
|
-25.14
|
-26.17
|
-19.94
|
-17.1
|
Operating Margin
|
-
|
-2,443.34%
|
-960.42%
|
-1,290.84%
|
-1,672.39%
|
-1,737.25%
|
-412.99%
|
-151.33%
|
Earnings before Tax (EBT)
1 |
-22.43
|
-31.19
|
-73.36
|
-18.61
|
-24.86
|
-25.84
|
-19.96
|
-17.1
|
Net income
1 |
-22.43
|
-29.93
|
-64.1
|
-72.9
|
-28.72
|
-26.69
|
-20.62
|
-19.1
|
Net margin
|
-
|
-2,461.51%
|
-829.52%
|
-1,301.82%
|
-1,911.04%
|
-1,772.04%
|
-427.13%
|
-169.03%
|
EPS
2 |
-8.800
|
-9.200
|
-14.40
|
-13.20
|
-3.750
|
-2.765
|
-1.700
|
-1.420
|
Free Cash Flow
|
-20.63
|
-27.21
|
-38.19
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-2,237.42%
|
-494.22%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/20
|
3/16/21
|
3/10/22
|
3/31/23
|
4/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
3.589
|
1.425
|
2.067
|
1.017
|
1.1
|
0.297
|
0.463
|
0.429
|
0.314
|
0.176
|
0.3124
|
0.4209
|
0.479
|
0.5341
|
0.9122
|
EBITDA
1 |
-7.018
|
-13.34
|
-9.826
|
-12.95
|
-11.06
|
-8.664
|
-5.438
|
-4.718
|
-4.671
|
-5.451
|
-0.9
|
-0.9
|
-1
|
-
|
-
|
EBIT
1 |
-35.68
|
-9.895
|
-8.562
|
-9.221
|
-44.66
|
2.872
|
-8.294
|
-6.513
|
-16.18
|
-9.267
|
-5.601
|
-5.572
|
-5.713
|
-5.312
|
-5.035
|
Operating Margin
|
-994.15%
|
-694.39%
|
-414.22%
|
-906.69%
|
-4,060.36%
|
967%
|
-1,791.36%
|
-1,518.18%
|
-5,152.55%
|
-5,265.34%
|
-1,793.07%
|
-1,323.81%
|
-1,192.8%
|
-994.61%
|
-551.94%
|
Earnings before Tax (EBT)
1 |
-35.79
|
-10.29
|
-8.3
|
-9.333
|
9.312
|
5.959
|
-8.333
|
-6.489
|
-13.07
|
-9.129
|
-5.532
|
-5.503
|
-5.644
|
-5.293
|
-5.016
|
Net income
1 |
-35.88
|
-10.29
|
-8.3
|
-9.333
|
-44.98
|
3.033
|
-8.333
|
-6.489
|
-16.2
|
-9.129
|
-5.782
|
-5.753
|
-5.894
|
-5.293
|
-5.016
|
Net margin
|
-999.86%
|
-722.25%
|
-401.55%
|
-917.7%
|
-4,088.91%
|
1,021.21%
|
-1,799.78%
|
-1,512.59%
|
-5,157.64%
|
-5,186.93%
|
-1,851.01%
|
-1,366.81%
|
-1,230.59%
|
-991.05%
|
-549.85%
|
EPS
2 |
-7.800
|
-2.200
|
-1.400
|
-1.600
|
-8.000
|
0.4000
|
-1.070
|
-0.8100
|
-2.070
|
-1.130
|
-0.5500
|
-0.4833
|
-0.8800
|
-0.4700
|
-0.4300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/11/22
|
8/10/22
|
11/10/22
|
3/31/23
|
5/11/23
|
8/10/23
|
11/9/23
|
4/12/24
|
5/15/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
19.4
|
3.92
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-20.6
|
-27.2
|
-38.2
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-72.7%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-56.3%
|
-67.5%
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
39.86
|
44.33
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
12.00
|
9.690
|
14.10
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-7.080
|
-8.060
|
-8.080
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.92
|
1.23
|
2.25
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
100.9%
|
29.08%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/20
|
3/16/21
|
3/10/22
|
3/31/23
|
4/12/24
|
-
|
-
|
-
|
Last Close Price
2.74
USD Average target price
4.062
USD Spread / Average Target +48.27% Consensus |
1st Jan change
|
Capi.
|
---|
| +9.60% | 36.62M | | -43.04% | 7.78B | | +12.75% | 3.73B | | -20.15% | 2.01B | | -22.61% | 1.63B | | +23.82% | 1.08B | | +24.08% | 776M | | -11.14% | 679M | | -29.59% | 508M | | -0.40% | 291M |
Bio Diagnostics & Testing
|